null

null

null

null

null

null

null

null

null

null

null

null

null

null

Pre-revenue clinical-stage biotech; minimal debt, primarily equity-financed; near-zero leverage ratio; 20% rate rise immaterial to debt cost

Interest rate sensitivity low; cash holdings in short-term treasuries/money market benefit marginally from rate increases; no variable-rate debt exposure

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

API source materials from contract manufacturers (CMOs); chokepoints are (1) India/China-based active pharmaceutical ingredient (API) synthesis and (2) specialized EU GMP excipient suppliers

No international revenue currently; clinical operations primarily U.S.-based; sovereign currency devaluation exposure is negligible

Effectively U.S.-only operations; no material international revenue markets; currency devaluation risk is not applicable at this stage

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Single CMO likely represents >50% of drug supply input; non-substitutable in short term without IND amendments and regulatory re-validation

Pharmaceutical R&D/clinical-stage; not cloud-infrastructure dependent for core operations; 30-day AWS termination would disrupt data systems but not drug development critically

Secondary model is potential licensing/partnership deals; cloud termination risk is low-severity given outsourced CRO/data management structures

Low API coupling risk; uses standard clinical data platforms (Medidata, Veeva); switching costs moderate but not mission-critical to pipeline IP

Revenue model is drug development/licensing; no token or investment contract structure; Howey Test risk is not applicable

Very High

Clinical trial patient data subject to HIPAA, GDPR (if EU trial sites used); CCPA exposure minimal; compliance risk moderate if EU sites enrolled

Single-asset clinical-stage company; no market dominance; antitrust exposure is negligible

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Currently pre-revenue; future revenue expected from milestone payments and royalties under licensing deals — 100% transactional/event-driven, not subscription

Monetization via pharma partnership milestones, royalties, and potential asset sale; no recurring SaaS or subscription revenue expected

Drug pricing will be set post-approval; oncology/rare disease pricing typically supports premium; pricing architecture not yet stress-testable

Oncology small-molecule drugs historically command strong pricing power if differentiated; elraglusib targets unmet need, supporting high list price potential

Post-approval pharma gross margins typically 70–90%; royalty/licensing model could yield 80–95% gross margin on partnered revenue

No free-rider risk; clinical-stage pipeline IP is proprietary; no open-access or freemium component exists

Highly sublinear; headcount-light model outsourcing clinical ops to CROs; doubling pipeline assets would not require proportional headcount growth

Marginal cost of growth driven by CRO and CMO contracts, not internal hiring; incremental trial costs non-linear but manageable through partnership structures

No franchise network; not applicable

At 10x scale (multiple approved drugs), CAC not applicable; partnership deal costs rise but royalty revenue scales with drug sales volume

No network effects present; drug development pipeline value does not compound with user/customer base growth

AI displacement risk low in near term; computational drug design tools may accelerate analogue screening but core GSK-3β IP is chemically proprietary

Oncology drugs are recession-resistant; cancer treatment demand inelastic; clinical funding risk moderate if capital markets tighten for biotech equity raises

Primary 'customers' are large pharma/biotech licensing partners (e.g., potential acquirers or co-development partners); highly concentrated counterparty risk

Secondary segment: oncology patients via hospital/oncology practice channel post-approval; payer/reimbursement risk is the key concentration concern

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital allocated almost entirely to forward-looking R&D (clinical trials); no legacy infrastructure to maintain; clean future-state capital deployment model

0001652935

ACTU